parallel randomized trial

S003428

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Overweight or obesity without diabetes (adults)S003428

Design

Randomized: 60
Start year
Treatment: 26.07 weeks, follow-up 26.07 weeks
Countries: Pakistan (1 sites)
Sponsor: (non industry)
Eligibility: overweight or obese adults 20 to 60 years; no cardiovascular disease, stroke, cancer or mental illness

Conduct and analysis

Blinding: open label
Sequence generation: computer
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population: randomized
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed
A1	Liraglutide 0.6 mg subcutaneous once daily Group A liraglutide 0.6 mg	lifestyle: standard	20	20
A2	Liraglutide 1.2 mg subcutaneous once daily Group B liraglutide 1.2 mg	lifestyle: standard	20	20
A3	Liraglutide 1.8 mg subcutaneous once daily Group C liraglutide 1.8 mg	lifestyle: standard	20	20

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Liraglutide 0.6 mg subcutaneous once daily A1	Liraglutide 1.2 mg subcutaneous once daily A2	Liraglutide 1.8 mg subcutaneous once daily A3	Whole trial ALL
age	mean (years)				56.60
age	sd (years)				2.30
bmi group:ii	mean (kg/m2)	30.21	29.87	28.59
bmi group:ii	sd (kg/m2)	1.56	2.56	2.22
bmi group:i	mean (kg/m2)	29.95	30.25	30.01
bmi group:i	sd (kg/m2)	1.35	1.56	2.14
female group:ii	n	7	6	5
female group:ii	percent	70	60	50
female group:i	n	6	7	7
female group:i	percent	60	70	70
hba1c group:ii	mean (percent)	5.67	6.34	6.79
hba1c group:ii	sd (percent)	1.18	2.37	1.98
hba1c group:i	mean (percent)	4.85	5.62	6.84
hba1c group:i	sd (percent)	1.35	1.28	2.22

Results

6 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (6 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	Events / N	Detail
26.07	A1	final	4.77 percent	1.2	10	not stated; randomized; group:i; R0053541:Table 2
26.07	A1	final	5.12 percent	1.08	10	not stated; randomized; group:ii; R0053541:Table 2
26.07	A2	final	5.12 percent	1.35	10	not stated; randomized; group:i; R0053541:Table 2
26.07	A2	final	5.15 percent	1.22	10	not stated; randomized; group:ii; R0053541:Table 2
26.07	A3	final	5.9 percent	1.5	10	not stated; randomized; group:i; R0053541:Table 2
26.07	A3	final	5.5 percent	2.5	10	not stated; randomized; group:ii; R0053541:Table 2